• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

40.77 +0.96 (+2.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Maze Therapeutics, Inc. - Common Stock

News headline image
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 06, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
November 06, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Participate in Four Upcoming Investor Conferences
November 04, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
October 06, 2025
Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into a leading clinical-stage biotech 
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
September 11, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
September 11, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
September 02, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
August 12, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
July 10, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
May 29, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
May 14, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
May 13, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
March 31, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
February 07, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap